Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Fasudil is a potent inhibitor of ROCK1, PKA, PKC, and MLCK.
Description | Fasudil is a potent inhibitor of ROCK1, PKA, PKC, and MLCK. |
Targets&IC50 | MLCK:55 μM(Ki), PKA:1.0 μM(Ki), PKC:9.3 μM(Ki), ROCK1:0.33 μM(Ki) |
In vitro | Fasudil (Hydrochloride) has vasodilatory action and occupies the adenine pocket of the ATP-binding site of the enzyme[1]. Fasudil is a class of calcium antagonists. Fasudil produces a competitive inhibition of the Ca2+-induced contraction of the depolarized rabbit aorta. Fasudil is able to inhibit contractile responses to KCl, phenylephnne (PHE) and prostaglandin (PG) F2a[2]. Fasudil also exhibits vasodilator actions by inhibition of 5-hydroxytryptamine, noradrenaline, histamine, angiotensin, and dopamine induced spiral strips contraction[3]. Fasudil induces disorganization of actin stress fiber and cell migration inhibition[4]. Fasudil inhibits hepatic stellate cells spreading, the formation of stress fibers, and expression of α-SMA with concomitant suppression of cell growth, but does not induce apoptosis. Fasudil suppresses the LPA-induced phosphorylation of ERK1/2, JNK and p38 MAPK[5]. |
In vivo | Fasudil (30 μg) produces an approximate 50% increase in CBF via intra-coronary injection to dogs. Fasudil (0.01, 0.03, 0.1 and 0.3 mg/kg, bolus, i.v.) dose-dependently decreases MBP and increases HR, VBF, CBF, RBF, and FBF. A total dose of 1.0 ng/mL Fasudil increases cardiac output. The infusion of Fasudil i.v. produces a significant fall in MBP, left ventricular systolic pressure and total peripheral resistance with an increase in HR and cardiac output, but without significant changes in right atrial pressure, dP/dt or left ventricular minute work in dogs[3]. Fasudil administration displays protectable effects on cardiovascular disease and reduces the activation of JNK and attenuates mitochondrial-nuclear translocation of AIF under ischemic injury[6]. The oral administration of Fasudil (a dosage of 100 mg/kg/day) significantly reduces incidence and mean maximum clinical score of EAE in SJL/J mice immunized with PLP p139-151. Treatment of mice with Fasudil suppresses the proliferative response of splenocytes to the antigen. Oral administration of Fasudil decreases inflammation, demyelination, axonal loss and APP positivein spinal cord of Fasudil-treated mice[7]. |
Kinase Assay | Cyclic AMP-dependent protein kinase activity is assayed in a reaction mixture containing, in a final volume of 0.2 mL, 50 mM Tris-HCl (pH 7.0), 10 mM magnesium acetate, 2 mM EGTA, 1 μM cyclic AMP or absence of cyclic AMP, 3.3 to 20 μM [r-32P] ATP (4×105 c.p.m.), 0.5 μg of the enzyme, 100 μg of histone H2B and compound. The mixture is incubated at 30°C for 5 min. The reaction is terminated by adding 1mL of ice-cold 20% trichloroacetic acid after adding 500 μg of bovine serum albumin as a carrier protein. The sample is centrifuged at 3000 r.p.m. for 15min, the pellet is resuspended in ice-cold 10% trichloro-acetic acid solution and the centrifugation-resuspension cycle is repeated three times. The final pellet is dissolved in 1 mL of 1 N NaOH and radioactivity is measured with a liquid scintillation counter[1]. |
Synonyms | AT877, 法舒地尔, HA-1077 |
Molecular Weight | 291.37 |
Formula | C14H17N3O2S |
CAS No. | 103745-39-7 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: Soluble
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Fasudil 103745-39-7 表观遗传 代谢 蛋白酪氨酸激酶 干细胞 离子通道 细胞骨架 细胞周期 自噬 Autophagy Calcium Channel PKA PKC ROCK Serine/threonin kinase LPA AT877 ROK Protein kinase C human HSC HA 1077 HA1077 Inhibitor ERK1/2 vasodilator Rho-associated kinase inhibit TIMP-1 protein kinases AT 877 lysophoaphatidic acid JNK rat HSCs collagen Ca2+ channel antagonist TWNT-4 cells Rho-associated protein kinase orally active Rho-kinase Protein kinase A Ca channels AT-877 HA-1077 a-SMA p38 Ca2+ channels inhibitor